Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation

NCT00989469 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Nexavar (Sorafenib) and irinotecan (Campto)

Sponsor

Institut du Cancer de Montpellier - Val d'Aurelle

Collaborators

[object Object]